[Importance of Zyrtec in the treatment of chronic urticaria and allergic rhinopathies apropos of 1168 cases seen by hospital practitioners].
This was a phase IV prospective trial involving out-patients from 80 hospital respiratory diseases and ENT departments, and 40 hospital dermatology departments. More than 1,000 cases were collected and used to evaluate the efficacy of Zyrtec at the dose of 10 mg per day. The aim of the trial was to assess the rapidity of action and good acceptability of treatment for 10 days and 2 weeks respectively in cases of seasonal and perennial rhinopathy. Similarly, in pruritic allergic skin disorders, the aim was to measure the degree of activity and acceptability of treatment for 2 weeks. Overall evaluation of results provided clinical evidence of satisfactory rapidity of action with an appreciable acceptability level. This prospective study confirms the good therapeutic index of Zyrtec as a new anti-allergic agent.
Billardon
M
M
Laboratoires Nanterre, France.
D000293:Adolescent; D000328:Adult; D017332:Cetirizine; D002908:Chronic Disease; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006919:Hydroxyzine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014581:Urticaria / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D006919:Hydroxyzine; D017332:Cetirizine
Intérêt du Zyrtec dans le traitement de l'urticaire chronique et des rhinopathies allergiques à propos de 1,168 cas réalisés par des praticiens hospitaliers.